Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0002007191-25-000065
Filing Date
2025-08-28
Accepted
2025-08-28 16:09:57
Documents
14
Period of Report
2025-08-04

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS zirc6kclr.htm 6-K 11999
2 EX-99.1 zircprcrl.htm EX-99.1 16646
3 EX-99.2 recastpdf.htm EX-99.2 898
4 GRAPHIC image1.gif GRAPHIC 35096
5 recastpdf1.jpg GRAPHIC 333746
6 recastpdf2.jpg GRAPHIC 250014
7 recastpdf3.jpg GRAPHIC 453431
8 recastpdf4.jpg GRAPHIC 250645
9 recastpdf5.jpg GRAPHIC 227969
10 recastpdf6.jpg GRAPHIC 213129
11 recastpdf7.jpg GRAPHIC 241212
12 recastpdf8.jpg GRAPHIC 232541
13 recastpdf9.jpg GRAPHIC 226428
14 recastpdf10.jpg GRAPHIC 165542
  Complete submission text file 0002007191-25-000065.txt   3652403
Mailing Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051
Business Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855
Telix Pharmaceuticals Ltd (Filer) CIK: 0002007191 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-42128 | Film No.: 251273481
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)